# GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma

> **NCT07670260** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Relapsed or Refractory Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** GoFast CD19 CAR T Cells

## Key facts

- **NCT ID:** NCT07670260
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670260, "GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*